Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart surgery bleeding study tests best drug dose

NCT ID NCT07164300

Disease control Sponsor: University of Ioannina Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study compares three different doses of the drug tranexamic acid in 150 adults having elective heart surgery with a heart-lung machine. The goal is to find which dose best controls bleeding and reduces the need for blood transfusions. Researchers will measure how long the drug works and its levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tranexamic acid
What this could lead to
If successful, this study could help doctors choose the best dose of tranexamic acid to reduce bleeding and transfusions during heart surgery.
What could go wrong
This is a small, early-phase trial with 150 participants. Different doses may not show clear benefits, and individual patient responses can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients undergoing elective cardiac surgery using cardiopulmonary bypass * Patients to have discontinued anticoagulant and antiplatelet therapy preoperatively according to guidelines. Exclusion Criteria: * Age below 18 years * Patient refusal * Pregnancy * End-stage renal disease * History of epilepsy, * Cardiac surgery without the use of cardiopulmonary bypass (off-pump) * Emergency operations * Known allergy to the administered agents.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adverse drug event are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

blood coagulation disease Drug-Related Side Effects and Adverse Reactions Hemorrhage Postoperative Hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adverse drug event Blood coagulation disorder Fibrinolysis; hemorrhage Postoperative blood loss Tranexamic acid adverse reaction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospital of Ioannina

    RECRUITING

    Ioannina, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.